Quick Dispatch:
Your tirzepatide surmount 1 SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount 1 SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants ships.
Need Help?
Questions about tirzepatide surmount 1 SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount 1 SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants in your area.
Tirzepatide's Surmount-4 Trial Reveals Groundbreaking Results
23.23
Frontiers
25.27
How Did Diabetes Medications Become Weight Loss Meds? Beyond Journal Club on SURMOUNT-1 Trial – Core IM Podcast
28.46
SURMOUNT Clinical Trials Orals Session
28.15
Tirzepatide cuts diabetes risk by 94% in SURMOUNT-1 trial
25.52
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
22.61
Semaglutide vs. Tirzepatide for Obesity
28.29
